On October 7, 2026, Salt Lake City-based Lipocine Inc. (NASDAQ: LPCN) said Health Canada has approved TLANDO (testosterone undecanoate) capsules as testosterone replacement therapy for adult men with a deficiency or absence of endogenous testosterone (male hypogonadism). The approval was obtained through Lipocine's licensing partner Verity Pharmaceuticals, which has held exclusive North American commercial rights since a January 2024 license deal and plans to launch in Canada by the end of 2026. Investing.com, via Yahoo Finance, reported Lipocine shares up about 30% in premarket trading on the news.

Why It Matters

TRT is the fastest-growing and most contested part of men's sexual health. US testosterone prescriptions have risen sharply since 2020, the Pentagon is screening service members, and DTC telehealth brands are marketing testosterone as a lifestyle product. An oral, no-titration option lowers the friction that keeps men off injections and gels, and lower friction tends to suit high-volume telehealth models. The Canadian label sets clear limits. Two confirmed lab values are required, TRT isn't a fix for sexual dysfunction without documented deficiency, and benefit in older men with age-related decline isn't established. Platforms that sell testosterone as a libido or vitality product will run into those limits. Watch Verity's launch pricing and private-payer coverage, and whether Canadian telehealth operators build TLANDO funnels the way US platforms did with enclomiphene. The label's fertility warning matters for younger men too, since some of them are starting TRT just as they're trying to conceive.

The product pitch is convenience. TLANDO is an oral capsule (112.5 mg) on a fixed dose with no titration. Lipocine contrasts that with intramuscular injections, which hold the largest share of Canadian TRT prescriptions, and with topical gels, which it calls "messy to apply" and which carry a risk of transference to partners and children. "Men with low testosterone in Canada have been served largely by injections and topical gels," said Lipocine CEO Dr. Mahesh Patel. Verity CMO Dr. Neil Flesher said a fixed dose "can make treatment easier to start." TLANDO is already FDA-approved in the US.

The company sizes the market at more than 700,000 TRT prescriptions written annually in Canada, with about half of patients covered by private insurance. It argues that limited promotion of existing products leaves room for a new entrant. That is the company's own estimate and hasn't been independently verified.

The Health Canada labelling is conservative. TRT should not be used for non-specific symptoms unless deficiency is "clearly demonstrated by clinical features and confirmed by two separate validated biochemical assays." Testosterone deficiency must be established before TRT is used to treat sexual dysfunction. Efficacy in men 65 and older with age-related hypogonadism "has not been established." The label also warns that large androgen doses can suppress spermatogenesis.

Sources

Update — 2026-10-08

Initial entry — story first created.